Search For "drug controller general of india"
Clinical features, treatment received by children are inadequate to determ
Updated : 5 months, 2 weeks ago IST
New Delhi [India], October 15 (ANI): Drugs Controller General of India (DCGI) on Saturday replied to World Health Organisation (WHO) and said as per the recently formed technical committee, the clinical features and the treatment received by the children as shared by WHO so far are inadeq
Read More
Corbevax approved as precaution dose for adults vaccinated with Covaxin, C
Updated : 7 months, 3 weeks ago IST
New Delhi [India], August 10 (ANI): Union Health Secretary Rajesh Bhushan on Wednesday said that the Centre has approved Biological E's Corbevax as a precaution dose after completion of six months from the date of administration of the second dose of either Covaxin or Covishield vaccines
Read More
Corbevax heterologous COVID-19 booster expected to get final approval from
Updated : 7 months, 3 weeks ago IST
New Delhi [India], August 9 (ANI): The Union Government is considering giving its final approval to Corbevax's heterologous COVID-19 booster for 'Restricted Use in Emergency Situation' soon, sources said.
Read More
CBI arrests DCGI official in Rs 4 lakh bribery case
Updated : 9 months, 1 week ago IST
New Delhi [India], June 21 (ANI): The Central Bureau of Investigation (CBI) on Tuesday arrested one Drug Controller General of India (DCGI) official in the national capital for allegedly taking a bribe of Rs 4 lakh.
Read More
DCGI approves Corbevax as first heterologous COVID-19 booster shot for adu
Updated : 9 months, 4 weeks ago IST
Hyderabad (Telangana) [India], June 4 (ANI): Biological E. Limited, a Hyderabad-based pharmaceutical and vaccines company, on Saturday, announced that its Corbevax COVID-19 vaccine has been approved by the Drug Controller General of India (DCGI) as a heterologous COVID-19 booster dose for
Read More
Bharat Biotech asked to provide more data on COVID-19 vaccine Covaxin for
Updated : 11 months, 1 week ago IST
New Delhi [India], April 22 (ANI): The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its COVID-19 vaccine, Covaxin, for administering it to children aged between 2-12 years, sources said.
Read More
Subject Expert Panel recommends Corbevax COVID-19 vaccines for children ag
Updated : 11 months, 1 week ago IST
New Delhi [India], April 21 (ANI): The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has recommended restricted emergency use of Biological E's Corbevax COVID-19 vaccine for children aged 5-11, said sources on Thursday.
Read More
Expert panel of DCGI holds meet to discuss recommendations to use COVID-19
Updated : 11 months, 1 week ago IST
New Delhi [India], April 21 (ANI): The meeting of the Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) is underway to discuss recommendations on restricted emergency use of Bharat Biotech's Covaxin and Biological E's Corbevax COVID-19 vaccine for children aged
Read More
DCGI claims India on course to become global drugs hub
Updated : 11 months, 2 weeks ago IST
New Delhi [India], April 14 (ANI): Claiming that India is on course to become a 'global hub for medicines', Dr VG Somani, Drug Controller General of India (DCGI), said that there has been a fourfold increase in applications of the investigational new drugs in the country.
Read More
Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical
Updated : 11 months, 3 weeks ago IST
Mumbai (Maharashtra) [India] April 11 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited, an innovation-driven, global pharmaceutical company, announced that its subsidiary Glenmark Specialty S.A. (Glenmark) received approval from the Indian drug regulator, Drug Controller General of India (
Read More
Zydus Lifesciences gets DCGI approval for Oxemia drug
Updated : 1 year ago IST
Ahmedabad (Gujarat) [India], March 7 (ANI): Zydus Lifesciences on Monday said it has received approval from the Drug Controller General of India (DCGI) for a new drug application, Oxemia (Desidustat), a first-of-its-kind oral treatment in India for anemia associated with chronic kidney disea
Read More
DCGI approves Themis Medicare's VIRALEX for Covid-19 treatment
Updated : 1 year ago IST
New Delhi [India], March 5 (ANI/Target Media): In a landmark development for the treatment of COVID-19, Themis Medicare Ltd. (Themis), a Pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available, announced the approval of its a
Read More
